Table I.
Clinical ADCs utilizing “vc-MMAE”
| Ph | Originator | Licensee (L)/collaborator (C) | Common name | Specificity target name | Targeted disease |
|---|---|---|---|---|---|
| 3 | Seattle Genetics | Celldex (L) | CDX-011 | anti-GPNMB | breast cancer |
| 2 | Seattle Genetics | Progenics | anti-PSMA | prostate | |
| 2 | Seattle Genetics | Genentech | RG-7596 | anti-CD79b | NHL |
| 2 | Seattle Genetics | Genentech | RG-7593 | anti-CD22 | NHL |
| 2 | Seattle Genetics | Genentech | RG-7599 | anti-NaPi2b | ovarian cancer |
| 1 | Seattle Genetics | SGN-LIV1A | anti-Liv1 | LIV1+ breast cancer | |
| 1 | Seattle Genetics | Agensys(C) | ASG-22ME | Nectin-4 | solid tumors |
| 1 | Seattle Genetics | Agensys(C) | ASG-15ME | SLTRK6 | bladder cancer |
| 1 | Seattle Genetics | Genentech | RG-7450 | anti-STEAP1 | prostate |
| 1 | Seattle Genetics | Genentech | RG-7458 | anti-MUC16 | ovarian |
| 1 | Agensys | AGS67E | anti-CD37 | NHL, CLL, AML | |
| 1 | Seattle Genetics | GenMab | HuMax-TF | anti-TF | solid tumors |
| 1 | Seattle Genetics | Takeda | MLN-0264 | anti-GCC | gastrointestinal cancer |